Harmony BiosciencesHRMY
HRMY
About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Employees: 268
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
170% more repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 47
142% more call options, than puts
Call options by funds: $4.24M | Put options by funds: $1.76M
64% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 25
6% more funds holding
Funds holding: 231 [Q3] → 245 (+14) [Q4]
4.89% more ownership
Funds ownership: 87.5% [Q3] → 92.39% (+4.89%) [Q4]
9% less capital invested
Capital invested by funds: $1.99B [Q3] → $1.81B (-$176M) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$44
49%
upside
Avg. target
$53
81%
upside
High target
$70
138%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
UBS Ashwani Verma 26% 1-year accuracy 5 / 19 met price target | 63%upside $48 | Buy Maintained | 28 Apr 2025 |
Needham Ami Fadia 22% 1-year accuracy 35 / 159 met price target | 70%upside $50 | Buy Reiterated | 10 Apr 2025 |
HC Wainwright & Co. Patrick Trucchio 22% 1-year accuracy 42 / 187 met price target | 138%upside $70 | Buy Reiterated | 8 Apr 2025 |
Mizuho Graig Suvannavejh 32% 1-year accuracy 7 / 22 met price target | 49%upside $44 | Outperform Maintained | 18 Mar 2025 |
Deutsche Bank David Hoang 12% 1-year accuracy 2 / 17 met price target | 87%upside $55 | Buy Initiated | 11 Feb 2025 |
Financial journalist opinion
Based on 11 articles about HRMY published over the past 30 days
Neutral
Business Wire
1 day ago
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 6, 2025, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-267-6316 (domestic) or 203-518-9783 (international), and reference passcode HRMYQ125. It is recommended that you dia.
Positive
Zacks Investment Research
1 week ago
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect
NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Neutral
Business Wire
3 weeks ago
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evaluating the safety and effectiveness of ZYN002 in children, adolescents, and adults with Fragile X syndrome (FXS). The data showed clinically meaningful improvements in irritability-related symptoms prevalent in individuals with FXS. There are currently no U.S. Food & Drug Administration (FDA) ap.
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Reach Out
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Neutral
Accesswire
3 weeks ago
Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Neutral
Accesswire
3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Investors to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Neutral
Business Wire
3 weeks ago
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of novel therapies. Prior to Orbital, he was Chief Executive Officer of Spark.
Neutral
Accesswire
4 weeks ago
Harmony Biosciences Holdings, Inc. (HRMY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the Company") (NASDAQ:HRMY). Investors who purchased Harmony securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HRMY.
Charts implemented using Lightweight Charts™